OAM
CORT icon

Oppenheimer Asset Management’s Corcept Therapeutics CORT Stock Holding History

Oppenheimer Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,435
Closed -$19K – 1605
2018
Q4 		$19K Buy
+1,435
New +$19K ﹤0.01% 1468

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Oppenheimer Asset Management's CORT Position: Q1 2019 in Review

Oppenheimer Asset Management sold out of Corcept Therapeutics (CORT) in Q1 2019, closing a stake of 1,435 shares — an estimated $19K sold.

Oppenheimer Asset Management first reported a position in CORT in Q4 2018 and held it in 1 quarter. The position peaked at $19K in Q4 2018. 208 funds tracked by Wall St. Rank hold CORT as of Q1 2019.

  • Oppenheimer Asset Management reported no remaining Corcept Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Oppenheimer Asset Management sold 1,435 Corcept Therapeutics shares in Q1 2019, an estimated $19K.
  • Oppenheimer Asset Management first reported a position in Corcept Therapeutics in Q4 2018 and held it in 1 quarter.
  • Oppenheimer Asset Management's Corcept Therapeutics position peaked at $19K in Q4 2018.
  • 208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2019.

Based on Oppenheimer Asset Management's 13F filing for Q1 2019, filed 24 Apr 2019.